Reversible pegylation prolongs the hypotensive effect of atrial natriuretic peptide

Bioconjugate Chemistry

Volumn 19, Issue 1, 2008, Pages 342-348

  Nesher, Maoz ^a   Vachutinsky, Yelena ^b   Fridkin, Gil ^b   Schwarz, Yehuda ^a   Sasson, Keren ^b   Fridkin, Mati ^b   Shechter, Yoram ^b   Lichtstein, David ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BIOCHEMISTRY; CHAINS; CONTROLLED DRUG DELIVERY; PEPTIDES; RATS; TARGETED DRUG DELIVERY;

ATRIAL NATRIURETIC PEPTIDES; CLINICAL APPLICATION; HALF LIVES; IN-VIVO; NATRIURETIC PEPTIDES; PEGYLATION; PHYSIOLOGICAL CONDITION; PRODRUGS; SLOW RELEASE; WISTAR RAT;

BLOOD PRESSURE;

ADRENALIN; ATRIAL NATRIURETIC FACTOR; MACROGOL;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BOLUS INJECTION; CHEMICAL REACTION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; WISTAR RAT;

RATTUS; RATTUS NORVEGICUS;

EID: 38949083505     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc700294w     Document Type: Article

References (40)

1. Silver, M. A. (2006) The natriuretic peptide system: kidney and cardiovascular effects. Curr. Opin. Nephrol. Hypertens. 15, 14-21.
2. Nakayama, T. (2005) The genetic contribution of the natriuretic peptide system to cardiovascular diseases. Endocr. J. 52, 11-21.
3. Levin, E. R., Gardner, D. G., and Samson, W. K. (1998) Natriuretic peptides. N. Engl. J. Med. 339, 321-328.
4. McGrath, M. F., de Bold, M. L., and de Bold, A. J. (2005) The endocrine function of the heart. Trends Endocrinol. Metab. 16, 469-411.
5. Ahluwalia, A., MacAllister, R. J., and Hobbs, A. J. (2004) Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. Basic Res. Cardiol. 99, 83-89.
6. Antunes-Rodrigues, J., de Castro, M., Elias, L. L., Valenca, M. M., and McCann, S. M. (2004) Neuroendocrine control of body fluid metabolism. Physiol. Rev. 84, 169-208.
7. Potter, L. R., Abbey-Hosch, S., and Dickey, D. M. (2006) Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev. 27, 47-72.
8. Anand-Srivastava, M. B. (2005) Natriuretic peptide receptor-C signaling and regulation. Peptides 26, 1044-1059.
9. Corti, R., Burnett, J. C., Jr., Rouleau, J. L., RuschitzkaF., and Luscher, T. F. (2001) Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease. Circulation 104, 1856-1862.
10. Maisel, A. S. (2003) Nesiritide: a new therapy for the treatment of heart failure. Cardiovasc. Toxicol. 3, 37-42.
11. Suwa, M., Seino, Y., Nomachi, Y., Matsuki, S., and Funahashi, K. (2005) Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J. 69, 283-290.
12. Quaschning, T. (2005) Vasopeptidase inhibition for blood pressure control: emerging experience. Curr. Pharm. Des. 11, 3293-3299.
13. Burger, A. J., and Burger, M. R. (2002) Nesiritide (Scios). IDrugs 5, 703-709.
14. Vesely, D. L. (2006) Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer? Clin. Exp. Pharmacol. Physiol. 33, 169-176.
15. Messerli, F. H., and Nussberger, J. (2000) Vasopeptidase inhibition and angio-oedema. Lancet 356, 608-609.
16. Sackner-Bernstein, J. D., Skopicki, H. A., and Aaronson, K. D. (2005) Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111, 1487-1491.
17. Sackner-Bernstein, J. D., Kowalski, M., Fox, M., and Aaronson, K. (2005) Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293, 1900-1905.
18. Veronese, F. M., and Pasut, G. (2005) PEGylation, successful approach to drug delivery. Drug Discovery Today 10, 1451-1458.
19. Werle, M., and Bernkop-Schnurch, A. (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30, 351-367.
20. Roberts, M. J., Bentley, M. D., and Harris, J. M. (2002) Chemistry for peptide and protein PEGylation. Adv. Drug Delivery Rev. 54, 459-476.
21. Tsubery, H., Mironchik, M., Fridkin, M., and Shechter, Y. (2004) Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J. Biol. Chem. 279, 38118-38124.
22. Peleg-Shulman, T., Tsubery, H., Mironchik, M., Fridkin, M., Schreiber, G., and Shechter, Y. (2004) Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. J. Med. Chem. 47, 4897-4904.
23. Shechter, Y., Tsubery, H., Mironchik, M., Rubinstein, M., and Fridkin, M. (2005) Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice. FEBS Lett. 579, 2439-2444.
24. Kurfurst, M. M. (1992) Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal. Biochem. 200, 244-248.
25. Hunter, W. M., and Greenwood, F. C. (1962) Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature (London) 194, 495-496.
26. Rybczynska, A., Boblewski, K., Lehmann, A., Orlewska, C., Foks, H., Drewnowska, K., and Hoppe, A. (2005) Calcimimetic NPS R-568 induces hypotensive effect in spontaneously hypertensive rats. Am. J. Hypertension 18, 364-371.
27. Kort, J. J., and Koch, G. (1990) Receptors for atrial natriuretic peptide (ANP) and cyclic GMP responses in HeLa cells. Biochem. Biophys. Res. Commun. 168, 148-154.
28. Watt, V. M., and Yip, C. C. (1989) HeLa cells contain the atrial natriuretic peptide receptor with guanylate cyclase activity. Biochem. Biophys. Res. Commun. 164, 671-677.
29. de Bold, A. J., Borenstein, H. B., Veress, A. T., and Sonnenberg, H. (1981) A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28, 89-94.
30. Sasaki, A., Kida, O., Kangawa, K., Matsuo, H., and Tanaka, K. (1985) Hemodynamic effects of alpha-human atrial natriuretic polypeptide (alpha-hANP) in rats. Eur. J. Pharmacol. 109, 405-407.
31. Guimaraes, S., and Moura, D. (2001) Vascular adrenoceptors: an update. Pharmacol. Rev. 53, 319-356.
32. Hirata, Y., Ishii, M., Sugimoto, T., Matsuoka, H., Fukui, K., Sugimoto, T., Yamakado, M., Tagawa, H., Miyata, A., and Kangawa, K. (1988) Hormonal and renal effects of atrial natriuretic peptide in patients with secondary hypertension. Circulation 78, 1401-1410.
33. Shepherd, J., Jones, J., Takeda, A., Davidson, P., and Price, A. (2006) Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol. Assess. 10, 1-183, iii-iv, xi-xiv.
34. Rosendahl, M. S., Doherty, D. H., Smith, D. J., Carlson, S. J., Chlipala, E. A., and Cox, G. N. (2005) A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation. Bioconjugate Chem. 16, 200-207.
35. Caliceti, P., and Veronese, F. M. (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Delivery Rev. 55, 1261-1277.
36. Carpino, L., and Han, G. (1972) The 9-fluorenylmethoxycarbonyl amino-protecting group. J. Org. Chem. 37, 3404-3409.
37. Carpino, L., and Han, G. (1970) The 9-fluorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group. J. Am. Chem. Soc. 92, 5748-5749.
38. Yasujima, M., Abe, K., Kohzuki, M., Tanno, M., Kasai, Y., Sato, M., Omata, K., Kudo, K., Tsunoda, K., and Takeuchi, K., et al. (1985) Atrial natriuretic factor inhibits the hypertension induced by chronic infusion of norepinephrine in conscious rats. Circ Res. 57, 470-474.
39. Badalamenti, S., Borroni, G., Lorenzano, E., Incerti, P., and Salerno, F. (1992) Renal effects in cirrhotic patients with avid sodium retention of atrial natriuretic factor injection during norepinephrine infusion. Hepatology 15, 824-829.
40. Parkes, D. G., Coghlan, J. P., McDougall, J. G., and Scoggins, B. A. (1990) Effects of atrial natriuretic factor on pressor responsiveness to angiotensin II, norepinephrine, and vasopressin in conscious sheep. J. Cardiovasc. Pharmacol. 15, 16-21.